Reflect

Reflection Biotechnologies (ReflectionBio) is a patient-driven biotechnology company focused on developing gene therapies and other breakthrough treatments for rare and challenging diseases, with a primary emphasis on ocular conditions. Founded by a rare disease patient, the company operates under a unique "By Patients, For Patients" model, where patients play a proactive role in driving research and development. Its lead program, RBIO-101, is an AAV-based gene therapy designed to treat Bietti Crystalline Dystrophy (BCD), a blinding retinal disease caused by mutations in the CYP4V2 gene. ReflectionBio has received Orphan Drug Designation from the U.S. FDA for RBIO-101 and is advancing the candidate toward human clinical trials. The company collaborates with leading academic institutions, including Columbia University, to translate cutting-edge science into life-changing therapies.